BioCryst Pharmaceuticals Files 8-K
Ticker: BCRX · Form: 8-K · Filed: Dec 12, 2025 · CIK: 882796
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
BioCryst filed an 8-K on 12/12/25, check it for updates.
AI Summary
BioCryst Pharmaceuticals, Inc. filed an 8-K on December 12, 2025, reporting on other events and financial statements. The filing does not contain specific financial figures or details about the nature of the events reported.
Why It Matters
This filing indicates that BioCryst Pharmaceuticals has made a regulatory submission to the SEC, which may contain important updates for investors.
Risk Assessment
Risk Level: low — The filing is a standard procedural document without immediate financial implications or significant new information.
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- December 12, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 4505 Emperor Blvd., Suite 200 Durham, North Carolina 27703 (address) — Principal Executive Offices
FAQ
What specific events are being reported in this 8-K filing?
The filing indicates 'Other Events' and 'Financial Statements and Exhibits' as items being reported, but the specific details of these events are not provided in the excerpt.
When was this 8-K report filed?
The report was filed on December 12, 2025.
What is the principal business of BioCryst Pharmaceuticals, Inc.?
BioCryst Pharmaceuticals, Inc. is in the business of Biological Products (excluding diagnostic substances), as indicated by its SIC code [2836].
Where are BioCryst Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices are located at 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703.
What is the Commission File Number for BioCryst Pharmaceuticals, Inc.?
The Commission File Number for BioCryst Pharmaceuticals, Inc. is 000-23186.
Filing Stats: 479 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-12-12 07:51:38
Filing Documents
- f8k_121225.htm (8-K) — 41KB
- exh_991.htm (EX-99.1) — 14KB
- 0001171843-25-007909.txt ( ) — 254KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_121225_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On December 12, 2025, BioCryst Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has approved the Company's new drug application for the use of an oral pellet formulation of once-daily ORLADEYO (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema aged 2 to <12 years. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated December 12, 2025 entitled "BioCryst Announces FDA Approval of ORLADEYO (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioCryst Pharmaceuticals, Inc. Date: December 12, 2025 By: /s/ Alane Barnes Alane Barnes Chief Legal Officer